American Association for Cancer Research
Browse
00085472can182034-sup-204549_2_supp_5311604_pm4ssr.xlsx (59.78 kB)

Supplemental Tables 1,2,3 from LINC00261 Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response

Download (59.78 kB)
dataset
posted on 2023-03-31, 02:21 authored by Shandy Shahabi, Vishaly Kumaran, Jonathan Castillo, Zhengmin Cong, Gopika Nandagopal, Daniel J. Mullen, Alexander Alvarado, Michele Ramos Correa, Autumn Saizan, Riya Goel, Amrita Bhat, Sean K. Lynch, Beiyun Zhou, Zea Borok, Crystal N. Marconett

Supplemental Table T1. List of Primers for LINC00261 detection and cloning. Supplemental Table T2. Differentially expressed lncRNAs in LUAD versus primary AEC. Supplemental Table T3. Differentially expressed genes in H522-CMV-LINC00261 vs CMV-NEO control cells.

Funding

Norris Comprehensive Cancer Center core grant

NIH

History

ARTICLE ABSTRACT

Lung cancer is the leading cause of cancer-related death in the United States. Long noncoding RNAs (lncRNA) are a class of regulatory molecules whose role in lung carcinogenesis is poorly understood. In this study, we profiled lncRNA expression in lung adenocarcinoma (LUAD) cell lines, compared their expression with that of purified alveolar epithelial type II cells (the purported cell of origin for LUAD), cross-referenced these with lncRNAs altered in the primary human tumors, and interrogated for lncRNAs whose expression correlated with patient survival. We identified LINC00261, a lncRNA with unknown function in LUAD, adjacent to the pioneering transcription factor FOXA2. Loss of LINC00261 was observed in multiple tumor types, including liver, breast, and gastric cancer. Reintroduction of LINC00261 into human LUAD cell lines inhibited cell migration and slowed proliferation by inducing G2–M cell-cycle arrest, while upregulating DNA damage pathway genes and inducing phosphorylation-mediated activation of components of the DNA damage pathway. FOXA2 was able to induce LINC00261 expression, and the entire locus underwent hypermethylation in LUAD, leading to loss of expression. We have thus identified an epigenetically deregulated lncRNA, whose loss of expression in LUAD promotes the malignant phenotype and blocks activation of the DNA damage machinery, predisposing lung cells to cancer development. These findings identify LINC00261 as a tumor suppressor that blocks cellular proliferation by activating the DNA damage response and suggest that epigenetic therapy to inhibit DNA methylation may enhance treatment of LUAD.